Septerna
SEPN
36.00
+0.33
+0.93%
Septerna
US · SEPN
#2886 by market cap
Listed 2024
36.00
+0.33
+0.93%
Live - 5344 symbols - heartbeat 303s ago
· 2026-10-08 07:18
Pre-market
36.00
0.00%
After-hours
36.00
0.00%
- Market cap
- 1.68B
- P/E (TTM)i
- -67.92
- P/Bi
- 4.35
- EPSi
- -1.10
- Div yieldi
- 0.00%
- 52W posi
- 55%
Reader sentiment
Are you bullish or bearish on SEPN?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Good
- Altman Z-Score is 4.59, above the 3.0 "safe zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 4 years
Latest year +4,174.51% YoY
Margins
- Operating margin
- -175.83%
- Net margin
- -106.37%
Key ratios & quality
- Altman Z-Scorei
- 4.59
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | 0 | 151.00K | 1.08M | 45.95M |
| Gross profit | -- | -- | -- | -- |
| Selling & admin expenses | 5.92M | 9.72M | 16.56M | 29.16M |
| Research & development | 22.04M | 35.98M | 65.34M | 97.58M |
| Operating profit | -27.97M | -45.55M | -80.82M | -80.80M |
| Pretax profit | -27.68M | 4.87M | -72.30M | -48.87M |
| Tax | 0 | 691.00K | -498.00K | 12.00K |
| Net profit | -27.68M | 4.18M | -71.80M | -48.88M |
| Basic EPS | -1 | 0 | -7 | -1 |
| Diluted EPS | -1.42 | 0.03 | -7.26 | -1.10 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 219.00K | 119.00K | 21.50M | 24.12M | 26.52M | 26.75M |
| Gross profit | -- | -- | -- | -- | -- | -- |
| Selling & admin expenses | 6.86M | 6.91M | 7.12M | 8.28M | 10.29M | 8.45M |
| Research & development | 19.27M | 22.19M | 24.26M | 31.86M | 29.54M | 35.13M |
| Operating profit | -25.91M | -28.98M | -9.89M | -16.02M | -13.30M | -16.84M |
| Pretax profit | -21.48M | -24.84M | 8.17M | -10.73M | -8.30M | -12.06M |
| Tax | 0 | 0 | 0 | 12.00K | 337.00K | 973.00K |
| Net profit | -21.48M | -24.84M | 8.17M | -10.74M | -8.64M | -13.03M |
| Basic EPS | 0 | -1 | 0 | 0 | 0 | 0 |
| Diluted EPS | -0.49 | -0.56 | 0.18 | -0.24 | -0.19 | -0.29 |
Balance sheet
| Line item | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total current assets | 31.89M | 112.68M | 356.82M | 410.96M |
| Cash & ST investments | 30.61M | 88.48M | 350.92M | 391.09M |
| Inventory | -- | -- | -- | -- |
| Total assets | 36.12M | 130.87M | 456.55M | 596.19M |
| Total current liabilities | 5.54M | 6.91M | 12.85M | 86.93M |
| Short-term debt | 710.00K | -- | 1.85M | 2.21M |
| Long-term debt | -- | -- | -- | -- |
| Total liabilities | 80,320,000.00 | 169,241,000.00 | 36,507,000.00 | 214,261,000.00 |
| Total equity | -44.20M | -38.37M | 420.05M | 381.93M |
| Retained earnings | -50.76M | -46.58M | -118.37M | -167.25M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 342.47M | 334.14M | 491.68M | 410.96M | 368.06M | 396.15M |
| Cash & ST investments | 336.01M | 326.56M | 474.35M | 391.09M | 347.40M | 372.32M |
| Inventory | -- | -- | -- | -- | -- | -- |
| Total assets | 434.02M | 415.23M | 606.65M | 596.19M | 569.69M | 566.74M |
| Total current liabilities | 10.64M | 15.13M | 75.28M | 86.93M | 78.17M | 79.32M |
| Short-term debt | 1.94M | 2.03M | 2.12M | 2.21M | 2.31M | 2.41M |
| Long-term debt | -- | -- | -- | -- | -- | -- |
| Total liabilities | 33,754,000.00 | 37,674,000.00 | 217,922,000.00 | 214,261,000.00 | 191,230,000.00 | 180,016,000.00 |
| Total equity | 400.27M | 377.56M | 388.73M | 381.93M | 378.46M | 386.72M |
| Retained earnings | -139.85M | -164.69M | -156.52M | -167.25M | -175.89M | -188.92M |
Cash flow
| Line item | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Operating cash flow | -23.30M | -38.72M | -67.47M | 110.19M |
| Depreciation & amortization | 577.00K | 848.00K | 1.40M | 1.60M |
| Free cash flow | -24.59M | -41.60M | -69.57M | 109.67M |
| Dividends paid | -- | -- | -- | -- |
| Stock buybacks / issuance | -- | -1.00K | 302.79M | -1.00K |
| Ending cash balance | 31.47M | 89.39M | 239.10M | 121.63M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | -23.34M | -20.29M | 168.81M | -14.99M | -25.63M | -22.18M |
| Depreciation & amortization | 397.00K | 405.00K | 401.00K | 401.00K | 421.00K | 427.00K |
| Free cash flow | -23.73M | -20.35M | 168.79M | -15.05M | -26.47M | -22.18M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -- | -- | -1.00K | 0 | -- | -- |
| Ending cash balance | 210.95M | 190.22M | 320.89M | 121.63M | 72.51M | 85.57M |
Returns & efficiency
| Line item | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| ROE %i | -- | -- | -37.62 | -12.19 |
| ROA %i | -76.62 | 0.68 | -24.45 | -9.29 |
| ROIC %i | -- | -- | -38.12 | -16.08 |
| 5-year avg ROE %i | -- | -- | -- | -- |
| EBIT margin %i | -- | -30,165.56 | -7,518.42 | -175.83 |
| FCF / sales %i | -- | -- | -- | 238.67 |
| Current ratioi | 5.75 | 16.30 | 27.77 | 4.73 |
| Quick ratioi | 5.52 | 16.09 | 27.40 | 4.66 |
| Debt / assetsi | 1.97 | 9.60 | 5.58 | 3.96 |
| LT debt / equityi | -- | -- | 5.62 | 5.61 |
| Interest coveragei | -- | -- | -- | -- |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | -19.76 | -56.49 | -39.03 | -12.19 | -9.26 | -6.34 |
| ROA %i | -18.23 | -29.57 | -15.06 | -9.29 | -7.18 | -4.94 |
| ROIC %i | -21.36 | -58.79 | -43.84 | -16.08 | -11.63 | -9.04 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -9,339.10 | -14,071.07 | -405.95 | -175.83 | -94.37 | -56.68 |
| FCF / sales %i | -- | -- | 467.92 | 238.67 | 147.99 | 106.29 |
| Current ratioi | 32.19 | 22.09 | 6.53 | 4.73 | 4.71 | 4.99 |
| Quick ratioi | 31.71 | 21.76 | 6.46 | 4.66 | 4.63 | 4.90 |
| Debt / assetsi | 5.77 | 5.92 | 3.97 | 3.96 | 4.05 | 3.98 |
| LT debt / equityi | 5.77 | 5.97 | 5.66 | 5.61 | 5.49 | 5.21 |
| Interest coveragei | -- | -- | -- | -- | -- | -- |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
Revenue breakdown most recent period
Business
G protein-coupled receptor (GPCR) oral small molecule drug discovery100.00%
Quote time 2026-10-08 07:18:22 · For reference only, not investment advice and not tailored to your situation.